Maryland State Retirement & Pension System Sells 3,131 Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Maryland State Retirement & Pension System decreased its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 13.9% during the first quarter, Holdings Channel.com reports. The institutional investor owned 19,400 shares of the life sciences company’s stock after selling 3,131 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Integra LifeSciences were worth $427,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IART. Assenagon Asset Management S.A. grew its position in shares of Integra LifeSciences by 2,418.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company’s stock worth $39,581,000 after buying an additional 1,728,480 shares in the last quarter. Soleus Capital Management L.P. bought a new position in shares of Integra LifeSciences during the 4th quarter worth $28,940,000. Paradigm Capital Management Inc. NY grew its position in shares of Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock worth $32,457,000 after buying an additional 901,600 shares in the last quarter. Lord Abbett & CO. LLC grew its position in shares of Integra LifeSciences by 86.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock worth $30,210,000 after buying an additional 618,773 shares in the last quarter. Finally, Systematic Financial Management LP grew its position in shares of Integra LifeSciences by 40.7% during the 4th quarter. Systematic Financial Management LP now owns 860,563 shares of the life sciences company’s stock worth $19,518,000 after buying an additional 248,817 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 4.2%

Integra LifeSciences stock opened at $14.19 on Friday. The stock has a 50-day moving average of $12.65 and a two-hundred day moving average of $16.87. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. Integra LifeSciences Holdings Corporation has a one year low of $11.06 and a one year high of $27.13. The stock has a market cap of $1.11 billion, a PE ratio of -2.17, a price-to-earnings-growth ratio of 0.77 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%. The company had revenue of $415.61 million during the quarter, compared to analysts’ expectations of $395.06 million. During the same period last year, the business posted $0.63 earnings per share. The firm’s revenue was down .6% compared to the same quarter last year. On average, research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

IART has been the topic of a number of recent research reports. Wells Fargo & Company dropped their price objective on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price objective on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 6th. Finally, JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Friday, May 9th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $18.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.